Clin Osteol 2026; 31(3): 127-134 | DOI: 10.36290/clo.2026.019

The FRAX® 10-year fracture risk calculator. History and current status worldwide and in the Czech RepublicMain theme

Jan Rosa
Affidea Praha, s. r. o., a Univerzita Karlova, Lékařská fakulta v Hradci Králové

Introduction: BMD, as measured by DXA bone densitometry, is a sufficiently specific but insufficiently sensitive tool in relation to osteoporotic fractures. Incorporating other risk factors for osteoporotic fractures into the diagnostic process and treatment decision-making is essential from both clinical and pharmacoeconomic perspectives.

Methods: Literature review.

Results: The FRAX® web-based calculator, introduced in 2008, quantifies the 10-year risk of hip fracture and major osteoporotic fractures. Prediction is enhanced by incorporating mortality data. It can also be used based on a summary of clinical risk factors; it is not necessary to enter a BMD value. Fracture probability data are based on local fracture incidence and mortality data, which is also the case for the model adjusted for the Czech Republic.

Conclusion: The FRAX® tool is the most widely used fracture risk calculator globally and is often incorporated into pharmacoeconomic models and guidelines regarding the diagnosis and treatment of osteoporosis.

Keywords: FRAX®, fracture probability, osteoporosis, fracture, major osteoporotic fracture.

Accepted: September 15, 2026; Published: October 8, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rosa J. The FRAX® 10-year fracture risk calculator. History and current status worldwide and in the Czech Republic. Clinical Osteology. 2026;31(3):127-134. doi: 10.36290/clo.2026.019.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 50 CZK
    will be unlocked 8.10.2027

    References

    1. Nordin BEC. The definition and diagnosis of osteoporosis. Calcif Tissue Int. 1987;40:57-58. Go to original source...
    2. Watts NB. Understanding the Bone Mass Measurement Act. J Clin Densitom. 1999;2:211-217. Go to original source...
    3. Consensus development conference: Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med. 1993;94:646-650.
    4. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. report of a WHO study group. Geneva: World Health Organization; 1994. WHO Technical Report Series.843.
    5. World Health Organization. Prevention and management of osteoporosis: report of a WHO scientific group. Geneva: World Health Organization; 2003. WHO Technical Report Series. 921.
    6. Siris ES, Chen Y-T, Abbott TA, et al. Bone Mineral Density Thresholds for Pharmacological Intervention to Prevent Fractures. Arch Intern Med. 2004;164:1108-1112. Go to original source...
    7. Kanis JA, Johnell O, Oden A, et al. Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden. Osteoporos Int. 2000;11:120-127. Go to original source...
    8. Kanis JA, Mcloskey EV, Harvey NC, et al. Intervention thresholds and the diagnosis of osteoporosis. J Bone Miner Res. 2015;30:1747-1753. Go to original source...
    9. Kanis JA, Harvey NC, Johansson H, et al. Overview of fracture prediction tools. J Clin Densitom. 2017;20:444-450. Go to original source...
    10. Kanis JA, Mccloskey EV, Harvey NC, et al. The need to distinguish intervention thresholds and diagnostic thresholds in the management of osteoporosis. Osteoporos Int. 2023;34:1-9. Go to original source...
    11. Kanis JA, Johansson H, Harvey NC, McCloskey E. A brief history of FRAX. Archives of Osteoporosis. 2018;13:118. Go to original source...
    12. Kanis JA, Johnell O, Oden A, et al. Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone. 2000;27:585-590. Go to original source...
    13. Kanis JA, Johnell O, Oden A, et al. Prediction of fracture from low bone mineral density measurements overestimates risk. Bone. 2000;26:387-391. Go to original source...
    14. Kanis JA, Johnell O, De Laet C, et al. International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res. 2002;17:1237-1244. Go to original source...
    15. Kanis JA, Johnell O, Oden A, et al. Ten-year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int. 2001;12:989-995. Go to original source...
    16. Kanis JA, Oden A, Johnell O, et al. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int. 2001;12:417-427. Go to original source...
    17. Khan AA, Riemer HJA, Slart RHJA, et al. Osteoporotic Fractures: Diagnosis, Evaluation, and Significance From the International Working Group on DXA Best Practices. Mayo Clin Proc. 2024;99:1127-1141. Go to original source...
    18. Kanis JA, Johnell O, Odén A, et al. Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int. 2000;11:669-674. Go to original source...
    19. Kanis JA, on behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield; UK:2008b.
    20. Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004;35:375-382. Go to original source...
    21. Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007;18:1033-1046. Go to original source...
    22. Compston J, Cooper A, Cooper C, et al., on behalf of the National Osteoporosis Guideline Group (NOGG). Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 2009;62:105-108. Go to original source...
    23. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. National Osteoporosis Foundation; Washington, DC:2008:1-36.
    24. Dawson-Hughes B, Looker AC, Tosteson ANA, et al. The potential impact of new National Osteoporosis Foundation guidance on treatment patterns. Osteoporos Int 2010;21:41-52. Go to original source...
    25. Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, et al. National Osteoporosis Foundation Guide Committee. Cost-effective osteoporosis treatment thresholds: The United States perspective. Osteoporos Int 2008;19:437-447. Go to original source...
    26. Kanis JA, McCloskey EV, Johansson H, et al. The National Osteoporosis Guideline Group. Case finding for the management of osteoporosis with FRAX® - Assessment and intervention thresholds for the UK. Osteoporos Int 2008;19:1395-1408. Go to original source...
    27. Kanis JA, Harvey NC, Cooper C, et al. A systematic review of intervention thresholds based on FRAX. Arch Osteoporos 2016;11:25. Go to original source...
    28. El-Hajj Fuleihan G, Chakhtoura M, Cauley JA, Chamoun N. Worldwide fracture prediction. J Clin Densitom 2017;20:397-424. Go to original source...
    29. Gregson CL, Armstrong DJ, Avgerinou C, et al. The 2024 UK clinical guideline for the prevention and treatment of osteoporosis. Archives of Osteoporosis 2025;20:119. Go to original source...
    30. Štěpán JJ, Vaculík J, Pavelka K, et al. Hip fracture incidence between years 1981 and 2009 in the Czech Republic as a basis of the country-specific FRAX model. Calcif Tissue Int 2012;90:365-372. Go to original source...
    31. Committee for Medicinal Products for Human Use (CHMP). Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. London: CHMP;2006. Ref CPMP/EWP/552/95Rev.2.
    32. McCloskey EV, Johansson H, Oden A, et al. Denosumab reduces the risk of all osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX®. J Bone Miner Res 2012;27:1480-1486. Go to original source...
    33. Shepstone L, Lenaghan E, Cooper C, et al. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. Lancet 2018;391:741-747. Go to original source...
    34. McCloskey E, Shepstone L, Lenaghan E, Cooper C, et al. Management of patients with high baseline hip fracture risk by FRAX reduces hip fractures - a post hoc analysis from the SCOOP Study. J Bone Miner Res 2018;33:1020-1026. Go to original source...
    35. Turner DA, Khioe RFS, Shepstone L, et al. The costeffectiveness of screening in the community to reduce osteoporotic fractures in older women in the UK: Economic evaluation of the SCOOP Study. J Bone Miner Res 2018;33:845-851. Go to original source...
    36. Leslie WD, Lix LM, Johansson H, et al. Does osteoporosis therapy invalidate FRAX for fracture prediction? J Bone Miner Res 2012;27:1243-1251. Go to original source... Go to PubMed...
    37. Leslie WD, Orwoll ES, Nielson CM, et al. Estimated lean mass and fat mass differentially affect femoral bone density and strength index but are not FRAX independent risk factors for fracture. J Bone Miner Res 2014;29:2511-2519. Go to original source...
    38. Schini M, Johansson H, Harvey NC, et al. An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis. Journal of Endocrinological Investigation 2024;47: 501-511. Go to original source...
    39. Järvinen TLN, Sievänen H, Khan KM, Heinonen A, Kannus P. Shifting the focus in fracture prevention from osteoporosis to falls. BMJ 2008; 336:124-126. Go to original source...
    40. Järvinen TL, Michaëlsson K, Aspenberg P, Sievänen H. Osteoporosis: the emperor has no clothes. J Int Med 2015;277:662-673. Go to original source...
    41. Järvinen TL, Michaëlsson K, Jokihaara J, et al. Overdiagnosis of bone fragility in the quest to prevent hip fracture. BMJ 2015;350:h2088. Go to original source...
    42. Ford N, Norris SL, Hill SR. Clarifying WHO's position on the FRAX® tool for fracture prediction. Bulletin of the World Health Organization 2016;94:862. Go to original source...
    43. Gollogly L, Susan Norris S, Ford N. Correcting the record on a fracture risk assessment tool. N Engl J Med 2018;378:867-868. Go to original source...
    44. World Health Organization. WHO scientific group on the assessment of osteoporosis at primary health care level. Summary Meeting Report Brussels, Belgium, 5-7 May 2004. 2007. http:// www.who.int/chp/topics/Osteoporosis.pdf?ua=1 [Staženo 11. 5. 2026]
    45. Dušek L, Májek O, Pikner R, Palička V. Information support provided by IHIS CR for osteology, information about the intention of the project on secondary prevention of femoral fractures. Osteol Bull 2017;22:71.
    46. Johansson H, Pikner R, Rosa J, et al. Changes in hip fracture incidence in Czechia and implications for FRAX (Abstract). 26th World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO IOF-ESCEO);P675.

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.